Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Centaur abandons US for European IPO

Article Abstract:

Centaur Pharmaceuticals is attempting to raise at least $54 million (CFR80 million) by listing itself on the Swiss stock exchange, the SWX. Centaur's CFO Joseph Turner stated that the company opted for the SWX rather than the NASDAQ because the Swiss exchange offered high liquidity, experience in valuation of pharmaceutical firms and local institutional and private investors. Mr. Turner also attributed Centaur's Swedish pharmaceutical alliances as a reason for going public on the SWX. Centaur is developing a class of small molecules called NRTs (nitrone-related therapeutics) which are used for the treatment of such oxidative stress-related disorders as Parkinson's disease, Alzheimer's disease and AIDS dementia complex.

Comment:

Centaur Pharmaceuticals hopes to raise at least $54 mil by listing itself on the SWX

Author: Furst, Ingeborg
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1998
Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Switzerland, Drugs, Article, Centaur Pharmaceuticals Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Neuer Markt drives IPOs in Europe

Article Abstract:

Several pharmaceutical and biotech companies are launching an initial public offering in Europe including Actelion of Allschwil, Switzerland, which was able to raise SFR260 million (US$158.6 million) at the SWX New Market and at the Neuer Markt in Frankfurt, Germany.

Author: Spillman-Furst, Ingeborg
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
Europe

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Return of the Neuer Markt

Article Abstract:

German biotechnology companies Morphosys and MWG Biotech will launch initial public offerings at the Neuer Markt.

Author: Furst, Ingeborg
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1999
Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, Brief Article, MorphoSys AG, MWG Biotech GmbH

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Germany, Exchanges, Neuer Markt
Similar abstracts:
  • Abstracts: Are you on the ball with the Euro? Derivatives secrets. Washington's agenda for corporate America
  • Abstracts: Analytical Valan shoots for the stars. Steiner taps sectionalization. Crow seeks effective media mix
  • Abstracts: Drinking from the European cup. Adding insult to injury. Private functions
  • Abstracts: Brand orientation: a mindset for building brands into strategic resources
  • Abstracts: Brand building for photo retailers. Radium Photo celebrates 90 years. NAPET president leaps into retail
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.